tiprankstipranks
Genfleet Therapeutics (Shanghai), Inc. Class H (HK:2595)
:2595
Hong Kong Market
2595
Genfleet Therapeutics (Shanghai), Inc. Class H
RESEARCH TOOLSreports

Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Stock Forecast & Price Target

Compare
0 Followers
See the Price Targets and Ratings of:

2595 Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Genfleet
Therapeutics (Shanghai), Inc. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

2595 Stock 12 Month Forecast

Average Price Target

HK$51.00
▲(81.49% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Genfleet Therapeutics (Shanghai), Inc. Class H in the last 3 months. The average price target is HK$51.00 with a high forecast of HK$51.00 and a low forecast of HK$51.00. The average price target represents a 81.49% change from the last price of HK$28.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"HK$22","37":"HK$37","52":"HK$52","29.5":"HK$29.5","44.5":"HK$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$51.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,29.5,37,44.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.78,25.873846153846156,27.96769230769231,30.06153846153846,32.15538461538462,34.24923076923077,36.34307692307692,38.43692307692308,40.53076923076923,42.62461538461538,44.71846153846154,46.81230769230769,48.90615384615384,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.78,25.873846153846156,27.96769230769231,30.06153846153846,32.15538461538462,34.24923076923077,36.34307692307692,38.43692307692308,40.53076923076923,42.62461538461538,44.71846153846154,46.81230769230769,48.90615384615384,{"y":51,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.78,25.873846153846156,27.96769230769231,30.06153846153846,32.15538461538462,34.24923076923077,36.34307692307692,38.43692307692308,40.53076923076923,42.62461538461538,44.71846153846154,46.81230769230769,48.90615384615384,{"y":51,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1754006400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.3,"date":1756684800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40,"date":1759276800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.32,"date":1761955200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.4,"date":1764547200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.78,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$51.00Average Price TargetHK$51.00Lowest Price TargetHK$51.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BOCOM International Holdings Company Analyst forecast on HK:2595
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$51
Buy
81.49%
Upside
Reiterated
01/28/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from BOCOM International Holdings Company
Citic Securities Analyst forecast on HK:2595
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$55
Buy
95.73%
Upside
Reiterated
12/01/25
Citic Securities Reaffirms Their Buy Rating on Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BOCOM International Holdings Company Analyst forecast on HK:2595
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$51
Buy
81.49%
Upside
Reiterated
01/28/26
Genfleet Therapeutics (Shanghai), Inc. Class H (2595) Receives a Buy from BOCOM International Holdings Company
Citic Securities Analyst forecast on HK:2595
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$55
Buy
95.73%
Upside
Reiterated
12/01/25
Citic Securities Reaffirms Their Buy Rating on Genfleet Therapeutics (Shanghai), Inc. Class H (2595)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Genfleet Therapeutics (Shanghai), Inc. Class H

3 Months
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
1 Year
Unknown AnalystBOCOM International Holdings Company
Not Ranked
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a buy rating 2 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
2 Years
xxx
Success Rate
0/0 ratings generated profit
Average Return
0.00%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2595 Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Strong Buy
1
2
Buy
0
0
Hold
0
0
Sell
0
0
Strong Sell
0
0
total
1
2
In the current month, 2595 has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 2595 average Analyst price target in the past 3 months is 51.00.
Each month's total comprises the sum of three months' worth of ratings.

2595 Financial Forecast

2595 Earnings Forecast

The previous quarter’s earnings for 2595 were -HK$2.17.
The previous quarter’s earnings for 2595 were -HK$2.17.

2595 Sales Forecast

The previous quarter’s earnings for 2595 were HK$95.32M.
The previous quarter’s earnings for 2595 were HK$95.32M.

2595 Stock Forecast FAQ

What is HK:2595’s average 12-month price target, according to analysts?
Based on analyst ratings, Genfleet Therapeutics (Shanghai), Inc. Class H’s 12-month average price target is 51.00.
    What is HK:2595’s upside potential, based on the analysts’ average price target?
    Genfleet Therapeutics (Shanghai), Inc. Class H has 81.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Genfleet Therapeutics (Shanghai), Inc. Class H a Buy, Sell or Hold?
          Genfleet Therapeutics (Shanghai), Inc. Class H has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Genfleet Therapeutics (Shanghai), Inc. Class H’s share price target?
            The average share price target for Genfleet Therapeutics (Shanghai), Inc. Class H is 51.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$51.00 ,and the lowest forecast is HK$51.00. The average share price target represents 81.49% Increase from the current price of HK$28.1.
              What do analysts say about Genfleet Therapeutics (Shanghai), Inc. Class H?
              Genfleet Therapeutics (Shanghai), Inc. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Genfleet Therapeutics (Shanghai), Inc. Class H?
                To buy shares of HK:2595, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.